Reassuring Data on the Cardiovascular Risk in Adults With X-linked Hypophosphatemia Receiving Conventional Therapy
An erratum to this article was published (J Clin Endocrinol Metab, 18 Jan 2024 ↗)
Authors' conclusion
We found no elevated risk of developing hypertension or LVH in patients with XLH.
Study context
- Population
- Adults with X-linked hypophosphatemia (XLH), local single-centre cohort
- Participants
- 22 adults
- Outcome
- Composite of:
- Frequency of LVH
- Presence of high blood pressure
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
Hypertensive
9%
No left ventricular hypertrophy (LVH)
69%
Left ventricular mass >100 g/m²
1 patient
Median blood pressure
124 (115-130)/68 (65-80) mm Hg
Observational data: associations, not effects.
Secondary outcomes
Left ventricular remodeling
- Patients with left ventricular remodeling
- 25%
Pulse wave velocity
- Pulse wave velocity was normal in all patients
Serum phosphate
- Median serum phosphate (mmol/L)
- 0.57 (0.47-0.72)
FGF23
- Median FGF23 (pg/L)
- 94 (58-2226)
Skin and muscle sodium content by sodium MRI before and after burosumab (2 patients)
- No differences in skin and muscle sodium content before and after burosumab
Original publication
Reassuring Data on the Cardiovascular Risk in Adults With X-linked Hypophosphatemia Receiving Conventional Therapy. J Clin Endocrinol Metab. Published 16 October 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →